SRPT logo

Sarepta Therapeutics Inc. (SRPT)

$14.77

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SRPT

Market cap

$1.58B

EPS

-0.06

P/E ratio

--

Price to sales

0.95

Dividend yield

--

Beta

0.448969

Price on SRPT

Previous close

$15.13

Today's open

$15.11

Day's range

$14.59 - $15.14

52 week range

$14.59 - $24.68

Profile about SRPT

CEO

Michael Severino

Employees

835

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

107235848

Issue type

Common Stock

SRPT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on SRPT

Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance

Sarepta Therapeutics NASDAQ: SRPT expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business to fund development, CEO Michael Severino said at Guggenheim's Third Healthcare Innovation conference.

news source

MarketBeat • Nov 9, 2026

news preview

Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick Moss - Executive VP & Chief Commercial Officer Louise Rodino-Klapac - President of Research & Development and Technical Operations Ryan Wong - Executive VP & CFO James Richardson - Executive VP & Chief Medical Officer Conference Call Participants Adhiraj Chauhan - JPMorgan Chase & Co, Research Division Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Brian Abrahams - RBC Capital Markets, Research Division Lin Tsai - Jefferies LLC, Research Division Eliana Merle - Barclays Bank PLC, Research Division Joshua Fleishman - TD Cowen, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division David Hoang - Deutsche Bank AG, Research Division Tommie Reerink - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.

news source

Seeking Alpha • Nov 8, 2026

news preview

Sarepta Therapeutics Q3 Earnings Call Highlights

Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.

news source

MarketBeat • Nov 6, 2026

news preview

SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. “After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opport.

news source

Business Wire • Nov 5, 2026

news preview

Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to a loss of $0.13 per share a year ago.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in.

news source

Business Wire • Oct 26, 2026

news preview

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations.

news source

Business Wire • Oct 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Sarepta Therapeutics Inc.

Open an M1 investment account to buy and sell Sarepta Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SRPT on M1